high volume subcutaneous drug delivery   High Volume Subcutaneous Drug Delivery • Published May 2016  •  Catalog no. HVS383K  •  Price US $3,850


The trend favoring biological drugs as a percent of all drugs continues to accelerate. Most are injectables and many require volumes that exceed   1 mL per dose, the de facto limit for comfortable and safe patient self-administration. These large volume drug delivery  therapies have been restricted by the unmet need for  devices capable of addressing a new range of dosing volumes. As a result, the majority of new and emerging drugs with large dosage volume requirements are being supplied for delivery via infusion. The demographics of patient populations and the current trend in therapeutic drug development are converging to create an increasingly steep demand curve for infusion. The costs and logistics of this convergence are major drivers of the efforts to develop and commercialize high volume drug delivery products that can be administered subcutaneously. We expect the number of therapeutic drugs in this class to grow significantly by the end of the decade, creating significant opportunities for high volume subcutaneous drug delivery products.

Bar_Graph  High Volume SQ Drug Delivery Brochure (Download PDF)

Blue document High Volume SQ Drug Delivery Order Form (Download PDF)


What You Will Learn

• Provides detailed analysis of therapeutic injectables with high volume dosing requirements that have been developed for subcutaneous administration over extended time periods.
• Analyzes therapeutic demand drivers and evaluates product activity in eleven product segments
• Profiles devices for delivering high volume drugs subcutaneously and assesses design factors and material selection issues
• Examines high volume subcutaneous drug products in development, and analyzes their potential commercial impact
• Provides market data and forecasts to 2020
• Profiles injectable drug and device participants, their product development activities, business strategies, and corporate alliances and affiliations
• Evaluates the impact of economic, technology, and regulatory factors

 


High Volume Subcutaneous Drug Delivery – Summary of Contents

Executive Summary

The Market Opportunity

Drug Delivery Market Dynamics

Shifting Demographics

The Trend toward Self-Administration

The Cost and Logistical Burden of Out-patient Infusion

Innovation in Device Designs

Therapeutic Demand Drivers

Competitive Landscape

Risk Factors

 

High Volume Subcutaneous Market Segments

High Volume Dosing

Duration Dependent Dosing

 

Device Design Factors

Human Engineering/Ergonomics

Usability

Safety

Alerts/User Feedback

Disposable vs. Reusable

Electronic vs. Mechanical

Primary Drug Container

Lyophilized Drugs/Reconstitution

 

Key Therapeutic Sectors

Antibiotics

scPharmaceuticals

Autoimmune

AstraZeneca

Cardiology

scPharmaceuticals

Insulet

Hematology

Amgen

UCB

Immunology

CSL Behring

Octapharma

Grifols

Bio Products Laboratory

Metabolic Conditions

GlaxoSmithKline

Rhythm Metabolic

Italfarmaco

Neurology

AbbVie

NeuroDerm

Britannia

US Worldmeds

Oncology

Janssen

Roche

Other Therapeutic Segment

UCB Pharma

Takeda

Company Profiles


Useful Links

High Volume Subcutaneous Injection Tolerability